ZBIO (Zenas BioPharma) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zenas BioPharma's non-current deferred liabilities for the quarter that ended in Dec. 2024 was $0.00 Mil.

Zenas BioPharma NonCurrent Deferred Liabilities Historical Data

The historical data trend for Zenas BioPharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma NonCurrent Deferred Liabilities Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

NonCurrent Deferred Liabilities

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial				-	-	-	-	-

Zenas BioPharma NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.